SG11202105279SA - Methods of treating myeloproliferative disorders - Google Patents
Methods of treating myeloproliferative disordersInfo
- Publication number
- SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- myeloproliferative disorders
- treating myeloproliferative
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2018/062534 WO2020112086A1 (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105279SA true SG11202105279SA (en) | 2021-06-29 |
Family
ID=64734125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105279SA SG11202105279SA (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Country Status (8)
Country | Link |
---|---|
JP (2) | JP7453230B2 (en) |
KR (1) | KR20210095904A (en) |
AU (1) | AU2018451360B2 (en) |
BR (1) | BR112021010134A2 (en) |
CA (1) | CA3120973A1 (en) |
EA (1) | EA202191489A1 (en) |
SG (1) | SG11202105279SA (en) |
WO (1) | WO2020112086A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR084070A1 (en) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | BROMODOMINIUM INHIBITORS AND USES OF THE SAME |
CA2952830C (en) | 2014-06-20 | 2022-11-01 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
-
2018
- 2018-11-27 KR KR1020217019508A patent/KR20210095904A/en not_active Application Discontinuation
- 2018-11-27 JP JP2021530108A patent/JP7453230B2/en active Active
- 2018-11-27 WO PCT/US2018/062534 patent/WO2020112086A1/en active Application Filing
- 2018-11-27 EA EA202191489A patent/EA202191489A1/en unknown
- 2018-11-27 AU AU2018451360A patent/AU2018451360B2/en active Active
- 2018-11-27 CA CA3120973A patent/CA3120973A1/en active Pending
- 2018-11-27 BR BR112021010134-9A patent/BR112021010134A2/en unknown
- 2018-11-27 SG SG11202105279SA patent/SG11202105279SA/en unknown
-
2024
- 2024-03-07 JP JP2024034717A patent/JP2024063214A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022519425A (en) | 2022-03-24 |
WO2020112086A1 (en) | 2020-06-04 |
EA202191489A1 (en) | 2021-09-10 |
JP7453230B2 (en) | 2024-03-19 |
JP2024063214A (en) | 2024-05-10 |
AU2018451360B2 (en) | 2022-05-26 |
AU2018451360A1 (en) | 2021-06-10 |
BR112021010134A2 (en) | 2021-08-24 |
KR20210095904A (en) | 2021-08-03 |
CA3120973A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285151B1 (en) | Methods of treating fgf21-associated disorders | |
IL273693A (en) | Treatment of inflammatory disorders | |
IL264510A (en) | Methods and compositions for treatment of epileptic disorders | |
HK1259336A1 (en) | Methods for treating myeloproliferative disorders | |
IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
HK1256036A1 (en) | Methods for treating myeloproliferative disorders | |
IL281736A (en) | Methods of treating myeloproliferative disorders | |
IL267229A (en) | Methods of treating ocular disorders | |
IL267818A (en) | Methods for the treatment of neurological disorders | |
EP3621434A4 (en) | Methods of treating neuropsychiatric disorders | |
IL275654A (en) | Methods of treating disorders associated with castor | |
EP3897641C0 (en) | Treatment of movement disorders | |
IL269604A (en) | Pantids for treatment of autoimmune disorders | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
IL263080B (en) | Treatment of neurological disorders | |
IL281589A (en) | Methods of treating myeloproliferative disorders | |
HK1245671A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
SG11202105279SA (en) | Methods of treating myeloproliferative disorders | |
PL3654965T3 (en) | Methods of treating autoimmune microvascular disorders | |
GB201604359D0 (en) | Treatment of tissue disorders | |
IL268504A (en) | Methods of treating seizure disorders | |
GB2580145B (en) | Treatment of produced hydrocarbons | |
GB2580157B (en) | Treatment of produced hydrocarbons | |
SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
IL274132A (en) | Treatment of skin disorders |